| Thomas G Kenamond, MD | |
|
58 16th St, Suite 500, Wheeling, WV 26003-3660 | |
| (203) 234-1751 | |
| (304) 242-1752 |
| Full Name | Thomas G Kenamond |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Nephrology |
| Location | 58 16th St, Wheeling, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750342341 | NPI | - | NPPES |
| 11166B | Other | WV | HPUOV |
| 0076890000 | Medicaid | WV | |
| 000043718 | Other | WV | MT ST BLUE CROSS BS |
| 0434631 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 35052389 (Ohio) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 11166 (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Thomas G Kenamond, MD 58 16th St, Suite 500, Wheeling, WV 26003-3660 Ph: (304) 242-7751 | Thomas G Kenamond, MD 58 16th St, Suite 500, Wheeling, WV 26003-3660 Ph: (203) 234-1751 |
News Archive
Nanoparticles can function as carriers for medicines to combat lung cancer: Working in a joint project at the NIM (Nanosystems Initiative Munich) Excellence Cluster, scientists from the Helmholtz Zentrum München and the Ludwig-Maximilians-Universität in Munich have developed nanocarriers that site-selectively release medicines/drugs at the tumor site in human and mouse lungs.
A recent study found that many parents feel they lack the knowledge to adequately detect symptoms of head injuries in their children. Yet keeping young athletes off the field until they've fully healed from a concussion is key to preventing serious and potentially fatal complications.
Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, and revised the Rating Outlook to Negative from Stable.
Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.
Researchers at A*STAR's Singapore Immunology Network (SIgN) have discovered a new mechanism involving p53, the famous tumour suppressor, to fight against aggressive cancers.
› Verified 8 days ago
Andrew Kenneth Etzel, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2115 Chapline St, Wheeling, WV 26003 Phone: 304-234-8885 | |
Rawan F. Kassar, MD Nephrology Medicare: Medicare Enrolled Practice Location: 40 Medical Park Ste 404, Wheeling, WV 26003 Phone: 304-243-2984 Fax: 304-243-6306 | |
Julie Suzanne Bunner, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 58 16th St, Wheeling, WV 26003 Phone: 304-243-6410 Fax: 304-243-6411 | |
Marnie J Marker, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 58 16th St, Suite 500, Wheeling, WV 26003 Phone: 304-234-1751 Fax: 304-234-1752 | |
Dr. Deepak Hooda, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 10 Medical Park, Suite 104, Wheeling, WV 26003 Phone: 304-242-4800 Fax: 304-242-3580 | |
Dr. Edward Kin Chiu, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1307 Mt Dechantal Rd, Wheeling, WV 26003 Phone: 304-242-3043 Fax: 304-242-1422 | |
Charles Clark Milton, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: Wheeling Hospital Inc, 1 Medical Park, Wheeling, WV 26003 Phone: 304-243-3124 |